Answers are grounded in this paper and cite their sources.
Evaluates the effects of AXS-12 on symptoms and function in narcolepsy type 1, indicating potential benefits.
To evaluate secondary endpoints assessing symptom severity, mood, and daily functioning, from the Phase 3 Symphony trial of AXS-12 (reboxetine) in narcolepsy type 1 (NT1).
No takes yet. Share an insight, caveat, or question.
Thorpy et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: